Management of risk of breast carcinoma in postmenopausal women

N Biglia, E Defabiani, R Ponzone, L Mariani, D Marenco and P Sismondi

Abstract

Breast carcinoma is the most frequent tumor in the female population. Many factors can influence the risk of breast cancer; some of them, such as old age and breast cancer 1/2 (BRCA1/BRCA2) gene mutations, are associated with a fourfold increase in risk. A previous diagnosis of atypical ductal or lobular hyperplasia or having a first-degree relative with a carcinoma are factors associated with a two- to fourfold increase in risk. A relative risk between 1 and 2 is associated with longer exposure to endogenous hormones as a result of early menarche, late menopause and obesity, or with recent and prolonged use of hormone replacement therapy (HRT) or with behavioural factors such as high alcohol and fat intake.

Is it possible to modify breast cancer risk in postmenopausal women? Risk factors related to lifestyle can be changed, even if it is not clear whether modifying these behavioural factors during the postmenopausal period will influence the overall breast cancer risk. For instance, the influence of exogenous hormones throughout life (both oral contraceptives and HRT) should be evaluated according to the individual risk–benefit ratio.

The problem is even more complex for women who carry genetic mutations and for those who have close relatives with breast cancer, who may be candidates for risk reduction strategies. Prophylactic bilateral mastectomy is still controversial, but is frequently offered to or requested by this group of women and may be indicated in BRCA1/BRCA2 carriers. Chemoprevention with tamoxifen and with the new selective estrogen receptor modulators, namely raloxifene, is very promising and deserves a thorough discussion for all high-risk women.

Introduction

Breast carcinoma is the most frequent female tumor in industrialized countries. It is generally less frequent in non-industrialized countries and the lowest rates are recorded among Asiatic populations. Interestingly, in Japan the incidence is very low despite its high degree of industrialization (Hulka & Moorman 2001).

Many of the risk factors for breast cancer are well known and some of them substantially affect a woman’s chances of developing the disease. The most important factors are female gender and age. Approximately two out of three breast cancer cases are found after 55 years of age; among women between 75 and 79 years of age the incidence is one case for every 300 women per year (Ries et al. 1999). For a long time, the global death rate from breast cancer used to parallel incidence data. In 1990, there were approximately 300 000 breast cancer-related deaths in the world, more than half of which occurred in industrialized countries. At present, the annual death rate varies from 27/100 000 women in northern Europe to 4/100 000 women in Asia (Lacey et al. 2002). Since 1987, a 25% decrease in death rates has been recorded in the USA; this is probably due partly to earlier diagnosis and partly to the introduction of adjuvant therapies (Lacey et al. 2002).

Research has also been aimed at reducing the incidence of breast cancer, by changing the risk factors whenever possible, or by prescribing chemopreventive drugs. Surgical prophylaxis has been advocated and put in practice for women at very high risk, i.e. those who are carriers of genetic mutations.
Risk factors
The main risk factors for breast cancer are listed in Table 1.

Age
Age is the main risk factor for breast carcinoma. The incidence of the disease increases steadily from 29 up to 40–50 years of age; after the menopause, the risk continues to rise up to 75 years of age in the USA and in northern Europe, while in Japan there is a slow decrease of incidence after 45 years (Hulka & Moorman 2001). Multiple factors such as genetic susceptibility, differences in endogenous hormonal levels, lifestyle and dietary factors, hormone therapy and availability of mammography screening programmes can explain the variations observed in different countries (Fig. 1).

Family history
Family history of breast cancer is another important risk factor. Having a mother or a sister with breast cancer increases the risk of developing the disease by 2 to 3 times. If there is more than one affected relative, if the disease appears at a young age and if it is bilateral or associated with ovarian cancer, the risk increases further (Thompson 1994). Studies on families with high breast cancer incidence have shown that about 5–7% of all breast carcinomas are hereditary. It was previously thought that mutations of two genes, breast cancer 1 (BRCA1) and BRCA2, were associated with a 90% lifetime risk of developing the disease. Further population studies have shown that variants of these two genes have different penetrance. It is currently believed that women who are carriers of BRCA1 and BRCA2 mutations have a 37–85% cumulative risk of developing breast cancer before 70 years of age, as compared with a risk of 10% for the general population (Easton et al. 1993, Struwing et al. 1996, Fodor et al. 1998). BRCA-related tumors generally appear before 50 years of age, although it is not unusual to see patients diagnosed at a later age (Hulka & Moorman 2001).

Mammographic density
Mammographic density is a risk factor for breast cancer in both pre- and postmenopausal women. Based on data from the Breast Cancer Detection Demonstration Project (Byrne et al. 1995) and the Canadian National Breast Screening Study (Boyd et al. 1995), women with more than 75% of their breast area classified as ‘dense’ at mammography have an approximately fivefold greater risk of developing breast cancer than women with less than 5% of their breast area classified as dense. Breast density is increased in younger and thinner women and in both pre- and postmenopausal nulliparous. The use of hormone replacement therapy (HRT) in postmenopausal women doubles their chance of having dense breasts at mammography (Sala et al. 2000) compared with non-users (odds ratio (OR) 2.48, 95% confidence interval (CI) 1.32–4.61) and this may make early diagnosis more difficult. Consequently, it is still unclear if mammographic density modifications induced by HRT can be used as indicators of breast cancer risk for individual women.

Previous biopsy for benign breast disease
Benign breast disease (BBD) is a very common spectrum of conditions that include a wide range of clinical and histopathological aspects of the mammary gland, the most representative of which are cysts and fibroadenomas. Since most benign breast lumps are neither painful nor progressive and may regress spontaneously, women may be unaware that they carry palpable lumps in their breasts. Typically, women who do not self-examine their breasts have a lower breast cancer awareness. By contrast, women who present with cysts or fibroadenomas in the breasts are those who routinely practice self-examination and are well informed about breast cancer. The former group of women are likely to belong to a lower social class and to have families with no breast cancer cases, while the latter group is likely to include women of a higher social

Table 1 Risk factors for breast cancer (modified from Hulka & Moorman 2001).

<table>
<thead>
<tr>
<th>RR &gt; 4</th>
<th>RR 2–4</th>
<th>RR &lt; 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced age</td>
<td>One first-degree affected relative (mother, sister)</td>
<td>Endogenous estrogens (nulliparity, first pregnancy after 30 years old)</td>
</tr>
<tr>
<td>BRCA1–BRCA2 genetic mutation</td>
<td>Atypical ductal or lobular hyperplasia</td>
<td>Recent or continuous use of HRT</td>
</tr>
<tr>
<td>Two first-degree affected relatives (mother, sister)</td>
<td>Breast exposure to high radiation doses</td>
<td>Lifestyle (smoking, physical activity)</td>
</tr>
<tr>
<td>&gt; 75% of dense breast at mammography</td>
<td>High bone density</td>
<td></td>
</tr>
</tbody>
</table>

RR, relative risk.
class or those with a positive family history of breast cancer. As a result, women who undergo biopsies for BBD are likely to be of a higher social class or to have a family history of breast cancer. This explains why the self-diagnosis of a benign lump may be considered as an indirect marker of the presence of established risk factors. Indeed, women who have undergone a breast biopsy for BBDs, independent of the histological outcome, have a relative risk (RR) of developing carcinoma of 1.5–1.8 (Armstrong et al. 2000). Only in cases of atypical ductal or lobular hyperplasia does the risk increase to three- to fourfold. It must be emphasized that although the relative risk associated with atypical lesions is high, their incidence is quite low (less than 5% of biopsies for BBD). Finally, women with a previous diagnosis of lobular or ductal carcinoma in situ have a relative risk of 8–10 of developing breast cancer as compared with the general population (Dupont & Page 1985).

**Ionizing radiation**

The exposure of the mammary gland to ionizing radiation is a well-recognized risk factor for breast carcinoma. Studies on populations surviving the nuclear explosions of Hiroshima and Nagasaki have demonstrated an inverse relationship between risk and age at radiation exposure. Furthermore, the risk is dose-dependent and tends to decrease progressively over time (Tokunaga et al. 1994). These data were confirmed by studies of infants receiving high radiation doses to reduce the size of the thymus, studies of the repeated use of fluoroscopy for tuberculosis (Hildreth et al. 1989, Miller et al. 1989) and, more recently, studies of women undergoing radiotherapy for the treatment of Hodgkin’s disease (Clemens et al. 2000). Although modern mammographic equipment allows delivery of very modest radiation doses (200–400 mrad) to the breast, it is important to assess the radiation-risk side of the risk–benefit equation related to routine screening mammography over many years. Because of the low doses involved in screening mammography, the benefit–risk ratio for older women would still be expected to be large. Conversely, the estimated radiation risk for younger women requires careful assessment of every single risk factor, to identify those women who actually show a favorable risk–benefit ratio, before starting any routine mammography.

**Bone density**

Many epidemiological studies have shown a positive correlation between bone density and postmenopausal risk of breast carcinoma, probably mediated by the action of endogenous estrogens. Women with high bone density are also those who have a higher risk of developing breast carcinoma, with a relative risk that varies from 2.0 to 3.5 (Cauley et al. 1996, Zhang et al. 1997, Buist et al. 2001). To support this point, it has been observed that women who have had fractures in the last 5 years have a reduced

---

Figure 1 Age-adjusted incidence rates for breast cancer, 1988–1992, in four countries: USA (SEER registries), Sweden, Colombia (Cali) and Japan (Miyagi Prefecture) (modified from Hulka & Moorman 2001).
risk of breast cancer (RR = 0.85-0.55) (Persson et al. 1994, Newcomb et al. 2001).

**Anthropometric variables**

The influence of some anthropometric variables, such as height and weight, on the risk of developing breast cancer is still the subject of debate. A weak correlation between height in adulthood and risk of breast carcinoma has been reported in many studies, with RR values for postmenopausal women spanning from 1.3 to 1.9 (Friedenreich 2001). A recent analysis of seven prospective cohort studies reports a RR of 1.07 (CI = 1.03–1.12) for a 5 cm difference in height. Furthermore, women who reach their maximum height after 18 years have a lower risk of developing breast cancer compared with those reaching their maximum height before 13 years (OR = 0.7, 95% CI = 0.5–1.0) (van den Brandt et al. 2000). Height is correlated to genetic factors, diet, physical activity, age at menarche and exposure to endogenous estrogens; therefore, one could hypothesize that modifying these factors at a young age could reduce the risk of breast cancer in later years.

Many studies have shown that body weight is directly correlated to breast cancer risk in postmenopausal women; the RR varies, according to the individual studies, from 1.0 to 1.9 and up to 2.2 for patients with a positive family history of breast cancer (Friedenreich 2001). The association between body mass index (BMI) and cancer risk in postmenopausal women is not linear; the risk does not increase further when BMI reaches 28 kg/m² (RR = 1.26, 95% CI = 1.09–1.46) (van den Brandt et al. 2000). A slight weight gain is associated with an RR of 1.2 in postmenopausal women, whereas the increase is more pronounced for those who gain more weight (RR = 2.3) (Friedenreich 2001). Data retrieved from the Nurses’ Health Study confirm a significant association between high BMI and low breast cancer incidence before the menopause, and much weaker association after the menopause. However, a positive relationship between BMI and breast cancer risk was also seen among postmenopausal women provided they never used HRT (RR = 1.59 for BMI > 31 kg/m² vs BMI≤20 kg/m²; 95% CI = 1.09–2.32; P < 0.001). In particular, a high BMI at the age of 18 years was found to be associated with a lower breast cancer incidence both before and after the menopause. Weight gain after the age of 18 years was unrelated to breast cancer incidence before the menopause, but was positively associated with breast cancer incidence after the menopause. This positive relationship between risk and weight gain was limited to women who never used postmenopausal hormones; among these women, the RR was 1.99 (95% CI = 1.43–2.76) for a weight gain of more than 20 kg vs unchanged weight (P < 0.001) (Huang et al. 1997).

Weight loss after the age of 45 only reduces the breast cancer risk in postmenopausal women who had reached their maximum weight before 45 years of age (OR = 0.90, CI = 0.84–0.98 for 5 kg weight loss). In contrast, for women who reach their maximum weight after 45 years of age, a decrease in weight does not modify their risk (OR = 1.00, CI = 0.95–1.05 for 5 kg weight loss). Finally, cyclic variations do not seem to modify the risk of breast cancer in postmenopausal women (Trentham-Dietz et al. 2000).

**Lifestyle**

**Dietary fat intake**

The association between dietary fat intake and breast cancer risk is highly debated. Although a reduction of circulating estradiol, both in pre- and postmenopausal women, has been observed after the reduction of fat in the diet (Wu et al. 1999), more recent epidemiological studies have not shown a correlation between fat intake and the risk of breast cancer (Lee & Lin 2000, Smith-Warner et al. 2001, Byrne et al. 2002, Horn-Ross et al. 2002). Considering the difficulty both in quantifying and qualifying fat intake and in comparing results of observational studies, the Women’s Health Initiative in the USA has launched a randomized clinical trial that will allow calculation of the real value of this risk factor (The Women’s Health Initiative Study Group 1998).

**Alcohol consumption**

Most epidemiological studies have highlighted a positive association between alcohol intake and the risk of developing breast carcinoma in both pre- and postmenopausal women, with a RR varying from 1.1 to 4.0 (Singletary & Gapstur 2001). The risk is dose-dependent as demonstrated by the experimental observation that starting from an intake of 60 mg/day, there is a 9% risk increase for every 10 g increase in daily alcohol consumption (Smith-Warner et al. 1998). It has also been estimated that about 2% of breast cancers in the USA can be attributed to alcohol consumption (Tseng et al. 1999); in Italy this figure rises to 15% (Mezzetti et al. 1998).

In postmenopausal women who are not using HRT, serum levels of estradiol and androgens are only slightly increased by a moderate alcohol intake. In women drinkers who take HRT, estradiol concentration is even more increased by alcohol, since it is around 3.3 times higher than that in non-drinkers (Ginsburg 1999).
Phytoestrogens

The incidence of some cancers, including those of the breast, endometrium, prostate and colon, is lower in eastern than in western countries. It has been hypothesized that different dietary habits may explain, at least in part, these differences. Attention has been focused on soy and its derivatives; these represent a fundamental diet component in eastern populations and contain many biologically active substances including isoflavones. Isoflavones are part of the wide phytoestrogen family, natural compounds of vegetable origin endowed with estrogen-like activity. The results of epidemiological studies evaluating the association between soy-rich diets and breast carcinoma are contradictory. Some authors have shown a protective effect only in premenopausal women (Lee et al. 1992); others report that the effect is independent of the menopausal status (Wu et al. 1996, Torres-Sanchez et al. 2000) and yet others do not find any significant effect of soy isoflavones (Horn-Ross et al. 2001). A meta-analysis has recently evaluated nine studies (eight case-controls, and one cohort) published in the last 10 years that are characterized by a huge variability both in RR values and in the definition of ‘elevated intake of soy’. An analysis of all the data shows only a small risk reduction in women who had an elevated intake of soy. The favourable effect was limited to premenopausal women, while there appeared to be no association in postmenopausal women (Trock et al. 2000) (Table 2).

Smoking

No relevant relationship is reported by many studies evaluating the effect of smoking on the risk of breast carcinoma. Women smokers tend to be thinner, are more often infertile, go into earlier menopause and are prone to osteoporosis. All these factors should reduce the risk of breast carcinoma after the menopause. More recent studies have shown that smoking at younger ages (before 16–17 years) increases breast cancer risk by approximately 20%, independent of length of exposure (Baron et al. 1996, Marcus et al. 2000, Egan et al. 2002). The largest case–control study (based on 17000 breast cancer cases) reports a slight risk increase (RR = 1.17, 95% CI = 0.96–1.43) for postmenopausal women who started smoking before 16 years of age (Baron et al. 1996).

The effect of passive smoke is still debated; some authors report a positive correlation (Lash & Aschengrau 1999, Johnson et al. 2000), while others do not find any correlation (Wartenberg et al. 2000, Egan et al. 2002). A meta-analysis of 11 studies reported a RR of 1.41 (95% CI = 1.14–1.75), but given the available data it is difficult to establish a causal association (Khuder & Simon 2000).

Physical activity

The literature on the relationship between physical activity in the menopause and breast carcinoma is controversial. The problem is that there is no single method for quantifying physical activity and the period of life during which physical activity has a beneficial effect. Some recent data suggest, however, that an increase in physical activity can reduce the breast cancer risk of postmenopausal women (Dirx et al. 2001, Friedenreich et al. 2001, Lee et al. 2001).

Endogenous hormones

The correlation between estrogens and breast carcinoma has been known for a long time. Estrogens promote growth and progression of tumor cells in vitro. In women, early menarche and late menopause, and therefore longer exposure of the breast to estrogen, are associated with an increased breast cancer risk, whereas the risk is reduced by an early menopause, either natural or induced (Clemons & Goss 2001).

Women who have had one or more pregnancy and, in particular, if the first pregnancy was before 25 years of age, have a lower breast cancer risk compared with nulliparous women. The protective effect of pregnancy appears after 10–15 years, is maintained for a long time span and is probably the result of modifications of the mammary tissue during pregnancy. As a result, multiparity reduces breast cancer risk during the menopause (Hulka & Moorman 2001).

Conversely, there is a positive relationship between breast cancer risk after the menopause and concentration of estrogen and androgen in the serum and a negative relationship with the concentration of sex hormone binding globulin (The Endogenous Hormone and Breast Cancer Collaborative Group 2002).

Exogenous hormones

Oral contraceptives

A link between the use of oral contraceptives (OCs) and breast cancer risk was thought plausible for many years, despite the inconsistent results of epidemiological studies.

---

Table 2 Meta-analysis of studies on phytoestrogens and breast cancer risk (eight case controls and one cohort study) (modified from Trock et al. 2000).

<table>
<thead>
<tr>
<th>Type</th>
<th>OR</th>
<th>CI (95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All women</td>
<td>↓</td>
<td>0.87</td>
</tr>
<tr>
<td>Premenopausal</td>
<td>↓</td>
<td>0.80</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>↔</td>
<td>1.01</td>
</tr>
</tbody>
</table>

OR, odds ratio; CI, confidence interval.
The Collaborative Group on Hormonal Factors in Breast Cancer published a meta-analysis in 1996 on 54 epidemiological studies that showed a slight increase in risk (RR = 1.24, 95% CI = 1.15–1.33) in women taking OCs. The risk remained stable for 10 years after the end of treatment, and then returned to basal values. No correlation was observed to dose, different preparations, length of use, age at first use, age of diagnosis or family history of breast cancer (Collaborative Group on Hormonal Factors in Breast Cancer 1996a,b).

Most of these data consider cancers developing during the pre- or perimenopausal period; the possible correlation between OC use and breast carcinoma in postmenopausal women has still to be elucidated. Two cohort studies have shown that the RR is almost doubled in women with breast carcinoma diagnosed after 55 years and who had previously used OCs for long periods (Schuurman et al. 1995, Van Hoften et al. 2000).

Evidence is insufficient to give a conclusive opinion on the risk–benefit relationship of the ever-increasing use of OCs for treating premenopausal symptoms. A recent study showed no risk increase for women between 45 and 64 years of age who were taking OCs or had taken them in the past. These data are reassuring, but the number of women (40 cases, 26 controls) who used OCs over 45 years of age is too small to draw definite conclusions (Marchbanks et al. 2002).

The actual role of OC use in women with a positive family history or in carriers of BRCA1 and BRCA2 gene mutations is still to be investigated. A small study shows a RR of 3 for women with a first-degree relative (sister or mother) with breast cancer who took OCs before 1975 (i.e. with ethinylestradiol doses over 50 μg) (Grabrick et al. 2000). Another two studies, although small, found the same correlation for women carrying BRCA1 mutations (Ursin et al. 1997, Heimdal et al. 2002).

**Hormone replacement therapy**

There are over 50 epidemiological studies available today on HRT and breast tumors. Overall, the data are reassuring regarding short- to medium-term therapies (up to 5 years), while long-term HRT slightly increases breast cancer risk. The meta-analyses carried out in the last decade indicate a risk increase in the order of 20–30% for long-term treatments (over 8–15 years). The collaborative study that collected over 90% of the epidemiological data available in 1997 highlights how duration of treatment and time elapsed since last HRT use are crucial factors for determining the magnitude of the risk (Table 3). The risk increase for each year of HRT is very limited (RR = 1.023), and is slightly lower than that associated with each year of physiological ovarian activity in women who have never used HRT (RR = 1.028). Furthermore, it appears to be limited to slim women. Long-term HRT is responsible for only a moderate excess in breast tumors over those expected between the ages of 50 and 70 in the untreated population: 2 cases for every 1000 women taking HRT for 5 years from the age of 50 years (47 observed instead of 45 expected), 6 cases if HRT is used for 10 years and 12 cases if HRT is used for 15 years (Collaborative Group on Hormonal Factors in Breast Cancer 1997) (Fig. 2). Data from the recently published Women’s Health Initiative (WHI) Randomized Controlled Trial are consistent with previous observations, reporting a RR of 1.26 (95% CI = 1.00–1.59) after 5 years treatment with combined HRT, which translates into an excess of eight breast carcinomas for 10000 women per year of use (Writing Group for the Women’s Health Initiative Investigators 2002).

The most debated issue today is the possible impact on breast tumor risk of the different treatment modalities, i.e. administration route, dosage and compound used.

**Table 3** Relative risk (RR) of breast cancer for duration of use within categories of time since last use of HRT (from the Collaborative Group on Hormonal Factors in Breast Cancer 1997).

<table>
<thead>
<tr>
<th>Duration of use and time since last use</th>
<th>Cases/controls</th>
<th>RR</th>
<th>RR and 99% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never used</td>
<td>12467/23568</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Last use &lt; 5 years before diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration &lt; 1 years</td>
<td>368/860</td>
<td>0.99</td>
<td></td>
</tr>
<tr>
<td>Duration 1–4 years</td>
<td>891/2037</td>
<td>1.08</td>
<td></td>
</tr>
<tr>
<td>Duration 5–9 years</td>
<td>588/1279</td>
<td>1.31</td>
<td></td>
</tr>
<tr>
<td>Duration 10–14 years</td>
<td>304/633</td>
<td>1.24</td>
<td></td>
</tr>
<tr>
<td>Duration ≥ 15 years</td>
<td>294/514</td>
<td>1.56</td>
<td></td>
</tr>
<tr>
<td>Last use ≥ 5 years before diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration &lt; 1 years</td>
<td>437/890</td>
<td>1.12</td>
<td></td>
</tr>
<tr>
<td>Duration 1–4 years</td>
<td>566/1256</td>
<td>1.12</td>
<td></td>
</tr>
<tr>
<td>Duration 5–9 years</td>
<td>151/374</td>
<td>0.90</td>
<td></td>
</tr>
<tr>
<td>Duration ≥ 10 years</td>
<td>93/233</td>
<td>0.95</td>
<td></td>
</tr>
</tbody>
</table>
Different preparations have different metabolic and pharmacodynamic characteristics that could be important in modulating the proliferative effect of estrogens on the mammary gland. A positive relationship between breast cancer risk and estrogen dosage cannot be substantiated by data in the literature. Moreover, the majority of studies refer to oral estrogens; there are still limited epidemiological data on transdermal estrogens or nasal spray formulations. Recent studies suggest that the addition of a progestogen further increases the risk associated with estrogen-only regimens, independent of the drug and of the treatment scheme (Magnusson et al. 1999, Ross et al. 2000, Schairer et al. 2000).

Almost all epidemiological studies suggest that the prognosis is better for breast cancer patients who had previously used HRT or who were taking HRT at the time of diagnosis (Fig. 3). These data seem to suggest the existence of a favourable biological effect of hormonal therapy which could selectively induce the growth of less aggressive tumors. Nevertheless, it cannot be excluded that the better prognosis of HRT users derives from earlier diagnosis as a result of heightened clinical and radiological surveillance (Gapstur et al. 1999, Stallard et al. 2000).

At present, there is controversy about the use of HRT in women who are carriers of BRCA1 or BRCA2 gene mutations, especially for those who undergo premature menopause following prophylactic bilateral oophorectomy (Narod 2001). Some authors believe that the administration of exogenous estrogens should not significantly influence the breast cancer risk of BRCA carriers since they are more likely to develop undifferentiated and estrogen receptor negative tumors.

**Management of the risk in postmenopausal women**

Various factors can reduce the risk of breast carcinoma in postmenopausal women such as preventive surgery, chemoprevention and changes in lifestyle.

**Prophylactic surgery**

Prophylactic mastectomy is considered a potential approach to reduce the risk of breast carcinoma in women carriers of BRCA gene alterations. Recent studies report a 90% risk reduction after bilateral mastectomy in a group of carriers of BRCA1 and BRCA2 gene mutations, although breast cancer might still develop because of the presence of residual mammary tissue (Meijers-Heijboer et al. 2001). Prophylactic mastectomy, whether or not followed by reconstructive surgery, must be discussed case by case with the patient, who should be well informed about the risks related to the surgical operation, the psychological changes it may bring and the incomplete protection it provides. Nevertheless, several studies showed that proven BRCA mutation carriers did not express any regret if the prophylactic mastectomy followed adequate counselling nor did they report sexual function changes after surgery; conversely their fear of cancer was effectively relieved (Stefanek et al. 1995, Klijn et al. 1997, Borgen et al. 1998). Moreover, in another two studies, 35 and 17% of proven carriers of BRCA1 mutation declared an interest in prophylactic mastectomy, and 73 and 33% in prophylactic oophorectomy, shortly after disclosure of DNA-test results (results from Lerman et al. 1996 and Lynch et al. 1997 respectively). Women carriers of BRCA mutations must be informed that bilateral oophorectomy will normally also prevent ovarian cancer. Although salpingo-oophorectomy is highly effective, protection is not complete as peritoneal carcinomatosis may develop in peritoneal tissues sharing a common embryologic origin from the coelomic epithelium or micrometastases may have already been present before surgery. Furthermore, in premenopausal women, surgical castration reduces the risk of breast carcinoma as much as it lowers estrogen levels. The severe impact of an early
menopause on quality of life should be considered and discussed with the patient.

Chemoprevention

In 1998, results from the National Surgical Adjuvant Breast and Bowel Project-Breast Cancer Prevention Trial (NSABP-BCPT) (Fisher et al. 1998) led to Food and Drug Administration approval of the use of tamoxifen for the chemoprevention of breast cancer in healthy women at high risk. This study showed a 50% risk reduction of invasive carcinoma and ductal carcinoma in situ (DCIS) in the group treated for 5 years with 20 mg tamoxifen/day as compared with controls. This reduction was observed for all age groups and was significant for women with previous diagnosis of lobular carcinoma in situ (LCIS) and atypical hyperplasia or in women with a family history of breast cancer; the protective effect was limited to tumors with positive estrogen receptors. Among the favorable events, a 19% reduction in osteoporotic fractures was reported in the group taking tamoxifen. This study showed a 50% risk reduction of invasive carcinoma and ductal carcinoma in situ (DCIS) in the group treated for 5 years with 20 mg tamoxifen/day as compared with controls. This reduction was observed for all age groups and was significant for women with previous diagnosis of lobular carcinoma in situ (LCIS) and atypical hyperplasia or in women with a family history of breast cancer; the protective effect was limited to tumors with positive estrogen receptors. Among the favorable events, a 19% reduction in osteoporotic fractures was reported in the group taking tamoxifen. Incidence of myocardial infarction was the same in the two groups, but there was an excess of deep venous thrombosis in postmenopausal women and an increased risk of endometrial carcinoma (RR = 2.5) in the treated group compared with the placebo group.

Results of the BCPT study were not confirmed by two European studies (Powles et al. 1998, Veronesi et al. 1998). Many reasons can explain this discrepancy: the small numbers of events (70 in the English study, 49 in the Italian study), different eligibility criteria, the higher proportion of carcinomas with negative estrogen receptors in the European studies as compared with the BCPT trial and the high drop-out rate. Furthermore, women taking HRT were excluded from the BCPT trial, while 41% of women in the UK study and 14% in the Italian study were taking hormones for menopausal symptoms, together with tamoxifen. Veronesi et al. 1998 observed a significant reduction in number of breast cancers in the group treated with tamoxifen compared with the placebo group (6 cases vs 17) only in the subgroup of women who had also taken HRT. This encouraged Italian researchers to begin a new trial to evaluate the efficacy of tamoxifen at low doses (5 mg/day) in preventing breast carcinoma in healthy postmenopausal women treated with every kind of HRT for problems related to the menopause (HRT Opposed to Low-dose Tamoxifen Study (HOT Study)) (Veronesi et al. 2002). The IBIS trial confirmed the effectiveness of tamoxifen in reducing the incidence of breast cancer in healthy women. The investigators found a reduction of 32% of invasive breast cancers and DCIS in the tamoxifen group; interestingly they also reported that women taking HRT and tamoxifen had fewer unfavorable endometrial and...
The use of tamoxifen for the reduction of breast cancer risk (modified from Vogel et al. 2001)

<table>
<thead>
<tr>
<th>Women who may consider the use of tamoxifen for risk reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of lobular carcinoma in situ</td>
</tr>
<tr>
<td>History of ductal carcinoma in situ</td>
</tr>
<tr>
<td>History of atypical ductal or lobular hyperplasia</td>
</tr>
<tr>
<td>Premenopausal women with mutations in either the BRCA1 or BRCA2 genes or other predisposing genetic mutations</td>
</tr>
<tr>
<td>Women aged &gt; 35 years with Gail model 5-year probability of breast cancer &gt; 1.66%</td>
</tr>
</tbody>
</table>

...and transitory ischemia or in the presence of factors that may increase the risk of developing endometrial cancer.

In conclusion, the data available from all the breast cancer prevention trials are very promising and tamoxifen should be considered as a preventive drug to be prescribed in clinical practice in women with a higher than average risk of breast cancer, for whom it has a more favourable risk–benefit ratio.

Retinoids, natural or synthetic vitamin A-like substances, have shown anti-tumor activity in animal models, but clinical results have proved disappointing. In one study (Veronesi et al. 1999), breast cancer patients taking fenretinide, one of the less toxic retinoids, had no reduction in risk of contralateral neoplasia as compared with controls. Post-hoc analyses, however, showed a possible favourable effect in preventing breast carcinoma in premenopausal women (RR = 0.66, 95% CI = 0.41–1.079) and a non-significant opposite effect in postmenopausal patients (RR = 1.32, 95% CI = 0.82–2.15). In the light of these data, fenretinide cannot be prescribed as a chemopreventive agent for breast carcinoma.

A wide group of compounds known as selective estrogen receptor modulators (SERMs) has been extensively studied. SERMs are able to bind to and activate estrogen receptors (ERs) with tissue-specific effects, acting as estrogen agonists or antagonists according to the organ, tissue and physiological context. Raloxifene has been widely studied; like tamoxifen, it is a competitive ER antagonist in breast tissue. It also acts as a competitive antagonist in uterine tissue and as an agonist in bone. In addition, raloxifene lowers total and low-density lipoprotein cholesterol levels, but does not increase high-density lipoprotein cholesterol levels as estrogen does.

The suggestion to use raloxifene as a chemopreventive agent for breast cancer arose from the safety data analysis of the MORE trial (Cummings et al. 1999), a randomized, double-blind study where the primary aim was to evaluate the effect of raloxifene treatment on fractures in postmenopausal women with osteoporosis. The study showed the effectiveness of raloxifene in reducing the incidence of vertebral fractures and in increasing bone mineral density (Ettinger et al. 1999). Furthermore, after an average treatment period of 36 months, raloxifene was also found to reduce by 90% (RR = 0.10, 95% CI = 0.04–0.24) the risk of developing ER-positive tumors (Fig. 4) (Cummings et al. 1999). These results were subsequently confirmed after 4 years of therapy, with an 84% reduction of ER-positive breast carcinomas (RR = 0.16, 95% CI = 0.09–0.30) (Cauley et al. 2001).

In a further analysis of the MORE trial data, Cummings et al. 2002 showed that raloxifene reduced breast cancer incidence by 76% (95% CI = 53%–88%) in the group of women with high levels of endogenous estrogens, while cardiovascular events than those who had been treated with tamoxifen alone (Cuzick 2001).

There is controversy on the efficacy of tamoxifen in reducing breast cancer incidence in women with BRCA mutations. A recent case–control study has shown that adjuvant tamoxifen is associated with a 50% reduction of contralateral carcinoma in breast cancer patients with BRCA1 and BRCA2 gene mutations (Narod et al. 2000). Using a simulated cohort, Grann et al. 2000 estimated that a 30-year-old woman with gene mutations can prolong survival by 0.9 years if she undergoes bilateral ovariectomy, by 3.4 years if she undergoes bilateral mastectomy, and by 4.3 years if she undergoes both procedures compared with a woman who simply undergoes clinical surveillance. A 5-year tamoxifen treatment, even if started late, between 40 and 50 years, extends survival by 1.6 years, with fewer side-effects and a better quality of life compared with early castration or bilateral mastectomy (Grann et al. 2000).

Before starting chemoprevention it is important to evaluate the individual absolute breast cancer risk over a definite period of time. To this aim, the Gail model is a widely used tool, although it has not been validated in European populations. Once the risk is assessed, several other factors such as age, co-morbidities and factors that may increase tamoxifen side-effects and toxicity should be thoroughly considered. Indications for use of tamoxifen are listed in Table 4 (Vogel 2001).

As for the onset of side-effects, an overview of all tamoxifen prevention trials reported a 38% reduction in breast cancer incidence along with an increase of venous thromboembolic events (RR = 1.9) and endometrial cancers, which were mostly of low or intermediate grade and stage I (consensus relative risk = 2.4). Nevertheless, there was no increase in death from endometrial cancer, or cardiac (i.e. myocardial infarction and transitory ischemia) and vascular events except for pulmonary embolism (6 vs 2 in the tamoxifen prevention trials). Therefore, particular attention should be paid when using tamoxifen in women with a positive history for deep vein thrombosis, pulmonary embolism, myocardial infarction...
the risk of breast cancer did not change in the group of women with low endogenous estrogen levels. This finding led the authors to suggest that high estrogen concentrations are likely to stimulate breast cancer so that a greater impact of raloxifene is expected as compared with patients with low levels of endogenous estrogens.

Raloxifene is usually well tolerated and side-effects are limited to a higher frequency of hot flushes, cramps of the lower limbs and fluid retention. The most significant problem is the increased incidence of deep venous thrombosis and pulmonary embolism, similar to that observed with HRT and tamoxifen. Raloxifene has also elicited new cases of, or worsened, diabetes mellitus but it does not appear to increase the risk of endometrial carcinoma (Cummings et al. 2002). In a further analysis of the MORE trial data, the number of cardiovascular events (defined as all coronary and cerebrovascular events) did not increase after 1 year of raloxifene treatment. After 4 years, raloxifene also proved to be effective in reducing the risk of cardiovascular disease, at least in a series of 1035 high-risk patients (RR = 0.60, 95% CI = 0.38–0.95) (Barrett-Connor et al. 2002).

Based on these promising data, a new trial of chemoprevention comparing tamoxifen and raloxifene in high-risk women has been designed (STAR trial). This trial will allow a comparison of the benefits of these two drugs. An indirect comparison relying on the data obtained in the BCPT and MORE trials cannot be made as the populations in the two studies are completely different. In the American study women with a high risk of breast cancer were included and the power of the study derives from the large number of events (264 invasive tumors and 104 DCIS). In contrast, the MORE trial was carried out on women with osteoporosis and thus at lower risk of breast cancer. In the STAR trial, 22,000 postmenopausal women at high risk of breast cancer will be compared, but data will not be available for 7 years. As a consequence, despite the favourable data of the MORE trial, raloxifene cannot be currently prescribed as a chemopreventive drug for breast cancer.

**Modification in lifestyle**

The association between changes in lifestyle and modification of breast cancer risk has yet to be confirmed. High alcohol intake (more than three glasses a day) is the only dietary component significantly related to the risk of breast cancer. Other components, including fat intake, do not show any significant correlation with the risk of the disease. Similarly, there are no clinical data to assert that an increased intake of phytoestrogens may cause a reduction in breast cancer risk.

Although available data are limited, it is possible to recommend that postmenopausal women do not increase their weight as, in this particular period in life, this may be associated with a modest increase of breast cancer incidence. Therefore, correct dietary habits and regular physical activity, besides improving general health, may reduce the risk of developing breast cancer in postmenopausal women.

Smoking after the menopause does not seem to increase the risk of breast cancer; however, the benefits of giving up, as far as cardiovascular and lung disease risk are concerned, are enough to advise against continuing such activity.

**Conclusions**

The prevalence of breast carcinoma after the menopause is expected to increase in the future. Is it possible to give indications aimed at modifying the risk of breast cancer in this age group? Is it worthwhile to suggest a change in lifestyle? It has been calculated that about 10–16% of all breast cancers in postmenopausal women can be attributed to obesity and weight increase (Mezzetti et al. 1998). Women should, therefore, be encouraged not to increase their weight during the menopause, and to lose weight if
they are over their ideal size. Losing weight helps to lower breast cancer risk only for postmenopausal women who reached their maximum weight before 45 years, but has no impact if their weight increased after this age. In order to prevent obesity, an increase of physical activity and a reduction in caloric intake is recommended. At present, the only suggestion that can be made regarding the type of diet, is to decrease alcohol intake if it is currently more than one glass a day. Abstinence or drinking less than one glass a day are not necessarily advisable because of the beneficial effect that moderate alcohol intake has on the risk of cardiovascular disease, which represents the main cause of morbidity and mortality in women during the menopause. Some preliminary data also suggest that a higher emphasis should be placed on these recommendations for women on HRT. There are currently no scientific grounds to suggest that other dietary modifications in postmenopausal women, such as lowering fat intake or increasing the intake of foods rich in soy, can alter the risk of breast cancer.

The association between HRT use and breast cancer risk is not yet completely clear, but it is biologically reasonable that long-term treatments may influence, at least modestly, the incidence of the disease. Therefore, the risk–benefit ratio in cases of long-term treatments must be evaluated for each individual woman.

The possibility of modifying the risk of breast cancer in women at high risk because of genetic susceptibility, family history or previous atypical hyperplasia is today one of the most important fields of research. Prophylactic surgery and chemoprevention should be considered on a case-by-case basis taking into account the risk–benefit profile, and must be thoroughly discussed with each woman. In the USA, tamoxifen is registered as a preventive drug for breast cancer in healthy women, whereas in Europe this indication is still the subject of clinical research. Conversely, tamoxifen remains a mainstay in the treatment of advanced breast cancer both in the adjuvant and advanced settings. Therefore, the use of tamoxifen for breast cancer prevention in healthy postmenopausal women, outside controlled clinical trials, should be taken into consideration after a careful evaluation of risks and benefits; these should include absolute breast cancer risk and the presence of risk factors for endometrial carcinoma and cardiovascular and thromboembolic diseases. Studies are underway to evaluate the efficacy of low-dose tamoxifen with HRT for the prevention of breast carcinoma in healthy postmenopausal women. Although available data show an antagonistic estrogen action, raloxifene cannot be used to reduce the risk of breast carcinoma and should be prescribed at present only as a preventive measure and for the treatment of osteoporosis.

References


multiethnic population: the Bay Area Breast Cancer Study. 


www.endocrinology.org


Vogel VG 2001 Reducing the risk of breast cancer with tamoxifen in women at increased risk. *Journal of Clinical Oncology* 19 (Suppl 18) 87–92.


